GondolaBio
James Li currently serves as President at GondolaBio since August 2024. Previously, James held several positions at BridgeBio from March 2020 to August 2024, including Chief Business Officer for BridgeBioX, Head of China, and Vice President of Business Development and Operations. Prior experience includes an engagement manager role at McKinsey & Company from March 2017 to March 2020 and a PhD student at Stanford University from September 2012 to May 2017, where a Doctor of Philosophy in Biochemistry and Management Science and Engineering was earned. James also began a career at McKinsey & Company as an associate in the summer of 2015. Education culminated with a Bachelor of Science in Molecular Biophysics and Biochemistry from Yale University, completed in 2012.
This person is not in any teams
GondolaBio
GondolaBio is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for genetic diseases. Originally launched as BridgeBioX, a subsidiary of BridgeBio, GondolaBio secured $300M in private financing from external investors in 2024 and became an independent company within the BridgeBio ecosystem. The company aims to leverage cutting-edge biological research to create breakthrough medicines addressing high unmet needs across multiple therapeutic areas, including neurology, pulmonology, cardiology, nephrology, and endocrinology. Located on the Stanford Life Sciences campus, GondolaBio fosters a unique hybrid environment where top scientists from around the world collaborate with senior leadership and advisors, blending industry expertise with academic innovation.